中金：维持复锐医疗科技(01696)跑赢行业评级下调目标价至4.50港元

智通财经03-25

智通财经APP获悉，中金发布研报称，考虑达希斐处于商业化起步阶段，下调复锐医疗科技(01696)2026年经调整净利润16%至3,472万美元，引入2027经调整净利润3,922万美元。当前股价对应2026/2027年6.3倍/5.5倍经调整市盈率。维持跑赢行业评级，考虑近期板块估值中枢有所下移，该行下调目标价25%至4.50港元，对应7.9/6.9倍2026/2027年经调整市盈率，较当前股价有...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2622435500?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-25 10:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622435500","market":"us","top_or_hot":-1,"title":"中金：维持复锐医疗科技(01696)跑赢行业评级 下调目标价至4.50港元","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，中金发布研报称，考虑达希斐处于商业化起步阶段，下调复锐医疗科技(01696)2026年经调整净利润16%至3,472万美元，引入2027经调整净利润3,922万美元。当前股价对应2026/2027年6.3倍/5.5倍经调整市盈率。维持跑赢行业评级，考虑近期板块估值中枢有所下移，该行下调目标价25%至4.50港元，对应7.9/6.9倍2026/2027年经调整市盈率，较当前股价有...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1418507.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中金：维持复锐医疗科技(01696)跑赢行业评级 下调目标价至4.50港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中金：维持复锐医疗科技(01696)跑赢行业评级 下调目标价至4.50港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-25 10:19 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1418507.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，中金发布研报称，考虑达希斐处于商业化起步阶段，下调复锐医疗科技(01696)2026年经调整净利润16%至3,472万美元，引入2027经调整净利润3,922万美元。当前股价对应2026/2027年6.3倍/5.5倍经调整市盈率。维持跑赢行业评级，考虑近期板块估值中枢有所下移，该行下调目标价25%至4.50港元，对应7.9/6.9倍2026/2027年经调整市盈率，较当前股价有...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1418507.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01696","symbol_name":"复锐医疗科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1418507.html","article_id":"2622435500","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622435500","pubTimestamp":1774405154,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，中金发布研报称，考虑达希斐处于商业化起步阶段，下调复锐医疗科技2026年经调整净利润16%至3,472万美元，引入2027经调整净利润3,922万美元。维持跑赢行业评级，考虑近期板块估值中枢有所下移，该行下调目标价25%至4.50港元，对应7.9/6.9倍2026/2027年经调整市盈率，较当前股价有29.3%的上行空间。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"01696":"复锐医疗科技"},"translate_title":"CICC: Maintain Forui Medical Technology (01696) Outperform Rating and Lower Target Price to HK$4.50","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01696":1.5},"content_text":"智通财经APP获悉，中金发布研报称，考虑达希斐处于商业化起步阶段，下调复锐医疗科技(01696)2026年经调整净利润16%至3,472万美元，引入2027经调整净利润3,922万美元。当前股价对应2026/2027年6.3倍/5.5倍经调整市盈率。维持跑赢行业评级，考虑近期板块估值中枢有所下移，该行下调目标价25%至4.50港元，对应7.9/6.9倍2026/2027年经调整市盈率，较当前股价有29.3%的上行空间。中金主要观点如下：2025年业绩符合市场预期公司公布2025年业绩：收入3.65亿美元，同比增长5%;归母净利润0.19亿美元，同比下滑24%;经调整净利润0.31亿美元，同比增长8%，对应经调整净利率8.5%(YoY+0.3ppt)，符合市场预期。注射填充快速增长，海外地区除北美均实现稳健增长2025年公司医疗美容业务收入3.10亿美元(YoY+1%)，注射填充业务收入0.28亿美元(YoY+186%)，服务及其他收入0.27亿美元(YoY-11%);分地区看，全年欧洲收入0.56亿美元(YoY+12%)，北美洲收入1.11亿美元(YoY-19%)，亚太收入1.47亿美元(YoY+27%)，拉丁美洲收入0.14亿美元(YoY+36%)，中东及非洲收入0.36亿美元(YoY+5%)。长效肉毒正式进行商业化，期待放量带动收入增长根据公告，公司长效肉毒达希斐DAXXIFY于2025年6月和复星万邦订立供应框架协议推进商业化准备，2025年9月公司与复星万邦订立商业配送合作协议，2026年1月达希斐正式通过中国食品药品检定研究院质量标准检验并在同月完成首次临床应用，目前达希斐出库数量已过万件，使用数据稳步增长，该行期待产品快速放量带动公司整体收入增长。风险提示：商业化不及预期，竞争格局恶化，海外业务不及预期。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622435500","isCrawlerRequest":true}

中金：维持复锐医疗科技(01696)跑赢行业评级 下调目标价至4.50港元

精彩评论

中金：维持复锐医疗科技(01696)跑赢行业评级下调目标价至4.50港元